ClinicalTrials.gg
RecruitingNCT06378138Updated Nov 21, 2025

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)

A Phase 2/3 interventional study of ICP-248 and Orelabrutinib in Hematologic Malignancies, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 53 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
226
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 148 studies in Hematologic Neoplasms with a site in China — 75 open to participants now, 83 under way, 8 of them phase 3. Hematologic Neoplasms · China.

Planned enrollment
14th of 123
226 · median 56
Started
2024
with 15 others
Phase 2/3
7 of 148
4 open now
Primary completion
2030-11
later than 80 of 82 live
Registered
98th of 148
by date

Among the 148 studies in Hematologic Neoplasms with a site in China, this one is the 14th largest by planned enrollment of the 123 interventional ones that give a count, is one of 16 that started in 2024, is one of 7 in phase 2/3, reaches primary completion later than 80 of the 82 other live ones, and was the 98th registered.

Hematologic Neoplasms

1,445 studies on the registry are indexed under Hematologic Neoplasms; 420 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

75 of the 148 studies in Hematologic Neoplasms with a site in China are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 208 (66%) set no upper age limit and 78 (25%) stop at 75 or younger; 80 take children under 18; 34 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 148 studies in Hematologic Neoplasms with a site in China, or all of them as a file.
02

Study summary

Evaluate the safety, tolerability and pharmacokinetics of ICP-248 in Combination with Orelabrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

03

Conditions studied

  • Hematologic Malignancies
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 and ≤ 80 years.
  2. CLL/SLL is diagnosed by histopathology and/or flow cytometry according to the 2016 World Health Organization (WHO) classification criteria for lymphohematopoietic neoplasms or meeting the criteria of 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL 2018):
  3. Having an indication for treatment that meets the criteria for iwCLL 2018
  4. Subjects must have according to the Lugano 2014 Assessment Criteria.
  5. Patients with an (ECOG) performance status (PS) score of ≤ 2 and a of ≥ 6 months.
  6. Adequate hematologic function
  7. Patients with basically normal coagulation function
  8. Patients with adequate hepatic, renal, pulmonary and cardiac functions
  9. Subjects are able to communicate with the investigator well and to complete the study as specified in the study.
  10. Before the trial, the subjects shall understand the nature, significance, possible benefits, inconveniences and potential risks, as well as the study procedures of the trial in detail and voluntarily sign the written Form (ICF).

Exclusion criteria

Exclusion Criteria:

  1. Central nervous system involvement.
  2. Concomitant Richter transformation.
  3. Prior systemic treatment, excluding emergency pretreatment to reduce white blood cells and relieve leukostasis.
  4. Requireing continuous support or glucocorticoid therapy within 5 days.
  5. History of stem cell transplantation.
  6. Major organ surgery (excluding aspiration ) or significant trauma within 28 days prior to the first dose of the drug or require elective surgery during the trial.
  7. Presence of active infection that requires intravenous anti-infective therapy.
  8. or C virus infection.
  9. History of immunodeficiency disease or Significant cardiovascular disease
  10. Central nervous system disorders or Severe bleeding disorder
  11. Alcohol or drug dependence.
  12. Mental disorders or poor compliance.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
226 participants (estimated)

Study arms

  • Experimental
    ICP-248 in combination with Orelabrutinib

    Drug: ICP-248 · Drug: Orelabrutinib

Interventions

  • Eligible patients will receive ICP-248 orally as per the protocol,once daily for every 28 days as one treatment cycle

  • Eligible patients will receive Orelabrutinib orally as per the protocol,once daily for every 28 days as one treatment cycle

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs) and serious adverse events (SAEs) evaluation according to CTCAE V5.0 or iwCLL 2018 criteria

    Time frame: Up to 6 years

  2. Changes from baseline in pulse.

    Time frame: Up to 6 years

  3. Changes from baseline in blood pressure.

    Time frame: Up to 6 years

  4. Changes from baseline in ECG QRS interval.

    Time frame: Up to 6 years

  5. Changes from baseline in ECG QT interval.

    Time frame: Up to 6 years

07

Study locations

44 of 53 sites recruiting
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui 233004, China
    Recruiting
    • Yanli Yang · Contact
  • Anhui Provincial Hospital (The First Affiliated Hospital of University of Science and Technology of China)
    Hefei, Anhui 230001, China
    Recruiting
    • Xingbing Wang · Contact
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230022, China
    Recruiting
    • Jian Ge · Contact
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100191, China
    Recruiting
    • Hongmei Jing · Contact
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality 400016, China
    Recruiting
    • Xiaoqiong Tang · Contact
  • Xinqiao Hospital, the Second Affiliated Hospital of Army Military Medical University
    Chongqing, Chongqing Municipality 400037, China
    Recruiting
    • Xixi Xiang · Contact
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
    Recruiting
    • Zhenshu Xu · Contact
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
    Recruiting
    • Bing Xu · Contact
  • Gansu Provincial People's Hospital
    Lanzhou, Gansu 730000, China
    Recruiting
    • Qike Zhang · Contact
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510055, China
    Recruiting
    • Yang Liang · Contact
  • Guangdong General Hospital
    Guangzhou, Guangdong 510080, China
    Not yet recruiting
    • Wenyu Li · Contact
  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangdong 510515, China
    Not yet recruiting
    • Xutao Guo · Contact
  • The First Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi 530021, China
    Not yet recruiting
    • Jun Luo · Contact
  • The Affiliated Hospital of Zunyi Medical University
    Zunyi, Guizhou 563003, China
    Not yet recruiting
    • Mingqiang Ren · Contact
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050010, China
    Recruiting
    • Lihong Liu · Contact
  • The Affiliated Hospital of North China University of Science and Technology
    Tangshan, Hebei 063000, China
    Recruiting
    • Zhenyu 063000 Yan · Contact
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan 471003, China
    Recruiting
    • Ling Qin · Contact
  • Nanyang City Center Hospital
    Nanyang, Henan 473005, China
    Recruiting
    • Chao Li · Contact
  • Henan Provincial People's Hospital
    Zhengzhou, Henan 463599, China
    Recruiting
    • Zunmin Zhu · Contact
  • Henan Cancer Hospital
    Zhenzhou, Henan 450003, China
    Recruiting
    • Keshu Zhou · Contact
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430011, China
    Recruiting
    • Xiaoxi Zhou · Contact
  • Union Hospital Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
    Recruiting
    • Guohui Cui · Contact
  • Yichang Central People's Hospital
    Yichang, Hubei 443003, China
    Recruiting
    • Huili Cai · Contact
  • The Second Xiangya Hospital, Central South University
    Changsha, Hunan 410012, China
    Recruiting
    • Hongling Peng · Contact
  • Hunan Cancer Hospital
    Changsha, Hunan 410031, China
    Recruiting
    • Fang Zhou · Contact
  • Changzhou First People's Hospital
    Changzhou, Jiangsu 213003, China
    Not yet recruiting
    • Weiying Gu · Contact
  • Huai'an First People's Hospital
    Huai'an, Jiangsu 223300, China
    Recruiting
    • Chunling Wang · Contact
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
    Recruiting
    • Wei Xu · Contact
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
    Recruiting
    • Fei Li · Contact
  • Bethune First Hospital of Jilin University
    Changchun, Jilin 130061, China
    Recruiting
    • Ou Bai · Contact
  • The Second Hospital of Dalian Medical University
    Dalian, Liaoning 116023, China
    Recruiting
    • Xiuhua Sun · Contact
  • Shengjing Hospital affiliated to China Medical University
    Shenyang, Liaoning Liaoning, China
    Recruiting
    • Aijun Liao · Contact
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250012, China
    Recruiting
    • Ming Hou · Contact
  • Shandong Provincial Hospital
    Jinan, Shandong 250021, China
    Recruiting
    • Xiaosheng Fang · Contact
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
    Recruiting
    • Ji Ma · Contact
  • Jining First People's Hospital
    Jining, Shandong 272011, China
    Recruiting
    • Tongfeng Zhao · Contact
  • Linyi City Cancer Hospital
    Linyi, Shandong 276002, China
    Recruiting
    • Meifang Zheng · Contact
  • Huashan Hospital
    Shanghai, Shanghai Municipality 200040, China
    Recruiting
    • Yan Yuan · Contact
  • Shanghai Huashan Hospital
    Shanghai, Shanghai Municipality 201108, China
    Not yet recruiting
    • Yan Yuan · Contact
  • The Second Hospital of Shanxi Medical University
    Taiyuan, Shanxi 030001, China
    Not yet recruiting
    • Zhuanzhen Zheng · Contact
  • Shanxi Cancer Hospital
    Taiyuan, Shanxi 030013, China
    Not yet recruiting
    • Liping Su · Contact
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi’an, Shanxi 710004, China
    Recruiting
    • Jianli Wang · Contact
  • Shaanxi Provincial People's Hospital
    Xi’an, Shanxi 710068, China
    Recruiting
    • Yi Wang · Contact
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
    Recruiting
    • Kai Shen · Contact
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan 610072, China
    Recruiting
    • Xiaobing Huang · Contact
  • Yibin Second People's Hospital
    Yibin, Sichuan 644002, China
    Recruiting
    • Shihua Huang · Contact
  • Blood Diseases Hospital of Chinese Academy of Medical Sciences
    Tianjin, Tianjin Municipality 300020, China
    Recruiting
    • Tingyu Wang · Contact
  • Tianjin People's Hospital
    Tianjin, Tianjin Municipality 300120, China
    Not yet recruiting
    • Xingli Zhao · Contact
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin Municipality 300181, China
    Recruiting
    • Lihua Qiu · Contact
  • The Affiliated Cancer Hospital of Xinjiang Medical University
    Ürümqi, Xinjiang Uygur Autonomous Region 830000, China
    Recruiting
    • Shujuan Wen · Contact
  • The First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650032, China
    Recruiting
    • Mingxia Shi · Contact
  • The First Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
    Recruiting
    • Wenjuan Yu · Contact
  • The People's Hospital Affiliated to Ningbo University
    Ningbo, Zhejiang 315040, China
    Recruiting
    • Ying Lu · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Nov 2030, 78 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2024
First posted
Apr 22, 2024
StartActual
May 15, 2024
Primary completionEst.
Nov 25, 2030
CompletionEst.
Jul 25, 2031
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06378138
Responsible party
Sponsor
First posted
Apr 22, 2024
Start date
May 15, 2024
Primary completion
Nov 25, 2030 (estimated)
Completion
Jul 25, 2031 (estimated)
Last update
Nov 21, 2025

Study contacts

Alexia Lu
Contact
CO_HGRAC@innocarepharma.com
010-66609745

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mesutoclax

Start the discussion